GARD

In New Study, Duloxetine Was Equally Effective, Regardless of Switch Method, in Reducing Painful Symptoms in Ssri Non- or Partial-responders with Depression

SAN DIEGO, California, 23 May 2007 - The antidepressant duloxetinehydrochloride was equally effective in reducing painful symptoms indepressed patients who did not respond, or responded onlypartially, to treatment with a selective serotonin reuptakeinhibitor (SSRI), regardless of whether those patients wereswitched from an SSRI abruptly or gradually. This newdata was presented t...

Nektar Threraputics Announces Phase 2a Clinical Results Regarding the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative Hospital-Acquired Pneumonia Presented at the Annual American Thoracic Society International Conference

SAN FRANCISCO--(BUSINESS WIRE)--May 21, 2007 - Medicalprofessionals seeking to treat the serious and growing problem ofhospital-acquired gram-negative pneumonia may have a new weapon:NKTR-061 (inhaled-amikacin), which is a product candidate beingdeveloped by Nektar Therapeutics (Nasdaq:NKTR). Results of a Phase 2a clinical trial evaluating the use ofNKTR-061 (Inhaled Amikacin) to treat me...

Data Published in The Lancet Show Gardasil was 100 Percent Effective in Preventing High-Grade Vulvar and Vaginal Lesions Caused by HPV Types 16 and 18

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--May 17, 2007 - Resultspublished this week in The Lancet show that Merck's cervical cancervaccine, GARDASIL (Quadrivalent Human Papillomavirus (Types 6, 11,16, 18) Recombinant Vaccine) was 100 percent effective inpreventing high-grade vulvar and vaginal dysplasias caused by HPVtypes 16 and 18, two types strongly associated with these diseases.The 10...

New England Journal of Medicine Publishes New Data on Gardasil, Merck's Cervical Cancer Vaccine

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)-May 10, 2007--Today, theNew England Journal of Medicine is publishing results from twoPhase III studies of Merck's cervical cancer vaccine, Gardasil(Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18)Recombinant Vaccine). In the first study, Gardasil provided 100percent protection against cervical, vaginal and vulvar diseasescaused by the four H...

Gardasil Demonstrates Up to 100% Efficacy

- In the Prevention of Cervical Cancer and Other HumanPapillomavirus Related Diseases After an Additional Year of FollowUp in Large Phase III Clinical Studies Which Included More Than17,000 Women New England Journal of Medicine publishes the most comprehensiveand robust clinical data for any Human Papillomavirus vaccine LYON, France, 10th May2007 – New clinical st...

Clinical Trial Data (Phase 2a) Regarding Inhaled Amikacin Will Be Presented at American Thoracic Society International Conference

SAN FRANCISCO--(BUSINESS WIRE)--May 9, 2007 - Results of a Phase 2aclinical trial evaluating the potential of NKTR-061 (inhaledamikacin) to treat hospital acquired gram-negative bacterialpneumonia will be presented at the American Thoracic Society (ATS)International Conference, May 18 - 23, 2007, in San Francisco. WHO: Dr. Michael S. Niederman, MD, Chairman, Department of...

MabThera Significantly Increases Survival of Lymphoma Patients Regardless of Chemotherapy Regimen

Data published today in the Journal of the National CancerInstitute BASEL, Switzerland, 2 May 2007 - In a study published today inthe Journal of the National Cancer Institute, the innovative cancerdrug MabThera was shown to improve overall survival in patientswith lymphoma regardless of the chemotherapy regimen used.1 Thereview further s...